Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology & oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. For more information, please visit www.primemedicine.com. Position Overview We are seeking a Scientist to join our cystic fibrosis team to lead the assessments of in vitro and in vivo delivery to lung epithelial cells. This role will utilize primary 2D and 3D mammalian cell cultures and mouse tissues to evaluate AAV- and LNP-mediated delivery to target cells. This work will guide the selection of lead candidate components for both AAV and LNP drug candidates. We are looking for curious problem solvers who enjoy working on fast-paced, exciting projects, working within a team, and are passionate about developing gene editing technologies to improve human health. The ideal candidate will be on site 5 days a week in Cambridge, MA.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level
Education Level
Ph.D. or professional degree
Number of Employees
101-250 employees